Acute‐phase response · people with familial Mediterranean fever
1 finding from 1 review
Number of participants experiencing an attacka · people with colchicine‐resistant familial Mediterranean fever
Canakinumab probably leads to lower number of participants experiencing an attacka compared with placebo (moderate certainty).
1 finding from 1 review
Duration of attacks · people with colchicine‐resistant familial Mediterranean fever
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time between attacks · people with colchicine‐resistant familial Mediterranean fever
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Prevention of AA amyloidosis · people with colchicine‐resistant familial Mediterranean fever
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse drug reactions · people with colchicine‐resistant familial Mediterranean fever
1 finding from 1 review
Time between attacks · people with familial Mediterranean fever
1 finding from 1 review
Acute‐phase response · people with colchicine‐resistant familial Mediterranean fever
1 finding from 1 review
Prevention of AA amyloidosis · people with familial Mediterranean fever
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse drug reactions · people with familial Mediterranean fever
It is very uncertain whether colchicine (oral) changes adverse drug reactions compared with placebo (very low certainty).
1 finding from 1 review
Acute‐phase response · people with familial Mediterranean fever
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants experiencing an attacka · people with familial Mediterranean fever
Rilonacept showed no clear difference in number of participants experiencing an attacka compared with placebo (moderate certainty).
1 finding from 1 review
Duration of attacksa · people with familial Mediterranean fever
1 finding from 1 review
Time between attacks · people with familial Mediterranean fever
1 finding from 1 review
Participant‐reported pain relief of 50% or greater · adults with painful diabetic neuropathy
Topical clonidine (TC) showed no clear difference in participant‐reported pain relief of 50% or greater during longest compared with placebo (low certainty).
1 finding from 1 review
Participant‐reported pain relief of 30% or greater · adults with painful diabetic neuropathy
It is very uncertain whether topical clonidine (TC) changes participant‐reported pain relief of 30% or greater during longest compared with placebo (very low certainty).
1 finding from 1 review
Patient Global Impression of Change much or very much improved · adults with painful diabetic neuropathy
Topical clonidine (TC) showed no clear difference in much or very much improved on PGIC during longest compared with placebo (low certainty).
1 finding from 1 review
PGIC very much improved · adults with painful diabetic neuropathy
Topical clonidine (TC) showed no clear difference in very much improved on PGIC during longest compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with painful diabetic neuropathy
Topical clonidine (TC) showed no clear difference in withdrawals due to adverse events during longest compared with placebo (low certainty).
1 finding from 1 review
Number of participants reporting an adverse event · adults with painful diabetic neuropathy
Topical clonidine (TC) showed no clear difference in participants experiencing at least 1adverse event during longest compared with placebo (low certainty).
1 finding from 1 review